Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs

Pharmacotherapy

Volumn 31, Issue 2, 2011, Pages 164-192

  Lam, Masha S H ^a  

^a Kaiser Permanente Health Plan   (United States)

Author keywords

Bioavailability; Chemotherapy; Compounding; Extemporaneous; Oral anticancer drugs; Stability

Indexed keywords

ALTRETAMINE; AMINOGLUTETHIMIDE; ANASTROZOLE; AZATHIOPRINE; BEXAROTENE; BICALUTAMIDE; BUSULFAN; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; ERLOTINIB; ESTRAMUSTINE; ETOPOSIDE; EVEROLIMUS; EXEMESTANE; FINASTERIDE; FLUDARABINE; FLUTAMIDE; GEFITINIB; HYDROXYUREA; IMATINIB; ISOTRETINOIN; LAPATINIB; LENALIDOMIDE; LETROZOLE; LOMUSTINE; MEGESTROL; MELPHALAN; UNINDEXED DRUG;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STORAGE; FEEDING APPARATUS; HOME CARE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PALATABILITY; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; REVIEW; SINGLE DRUG DOSE; STEADY STATE; STORAGE TEMPERATURE; SWALLOWING; TABLET;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; PHARMACEUTICAL SOLUTIONS; POWDERS; SUSPENSIONS; TABLETS;

EID: 79551603996     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.2.164     Document Type: Review

References (182)

1. Bowers ML, Silberman G, Mortenson LE. Oral oncology products: barriers to successful adoption. Oncol Issues 2002;17:26-7.
2. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs 2003;7:158-62.
3. Nissen LM, Haywood A, Steadman KJ. Solid medication dosage form modification at the bedside and in the pharmacy of Queensland hospitals. J Pharm Pract Res 2009;39:129-34.
4. Wright D. Tablet crushing is a widespread practice but it is not safe and may not be legal. Pharm J 2002;269:132. (Pubitemid 34855170)
5. Wright D. Medication administration in nursing homes. Nurs Stand 2002;16:33-8.
6. Paradiso LM, Roughead EE, Gilbert AL, et al. Crushing or altering medications: what's happening in residential aged-care facilities? Australas J Ageing 2008;21:123-7.
7. Griffin E. Safety considerations and safe handling of oral chemotherapy agents. Clin J Oncol Nurs 2003;7:25-9.
8. BBC News. Crushing pills 'can prove fatal,' October 25, 2006. Available from http://news.bbc.co.uk/2/hi/health/6085192.stm. Accessed July 21, 2010.
9. Traynor K. Pediatric cancer chemotherapy formulations remain elusive. Am J Health Syst Pharm 2010;67:170-1.
10. Nahata MC. Lack of pediatric formulations. Pediatrics 1999;104;607-9.
11. Christiansen N, Taylor KM, Duggan C. Oral chemotherapy in paediatric oncology in the UK: problems, perceptions and information needs of parents. PharmWorld Sci 2008;30:550-5.
12. Pai V, Nahata MC. Need for extemporaneous formulations in pediatric patients. J Pediatr Pharmacol Ther 2001;6:107-19.
13. Kairuz TE, Gargiulo D, Bunt C, Garg S. Quality, safety and efficacy in the 'off-label' use of medicines. Curr Drug Saf 2007;2:89-95.
14. Standing JF, Tuleu C. Paediatric formulations: getting to the heart of the problem. Int J Pharm 2005;300:56-66. (Pubitemid 41112167)
15. Chan A, Leow YC, Sim MH. Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center. J Oncol Pharm Pract 2009;15:161-5.
16. Thomson Reuters. DRUGDEX system (intranet database), version 5.1. Greenwood Village, CO: Thompson Reuters, 2010.
17. Lexi-Comp, Inc. Lexi-Comp online, pediatric Lexi-Drugs online. Hudson, OH: Lexi-Comp, Inc., 2010.
18. Bristol-Myers Squibb. Megace (megestrol acetate) oral suspension product information. Princeton, NJ; 2007.
19. Savient Pharmaceuticals, Inc. Soltamox (tamoxifen citrate) oral solution product information. East Brunswick, NJ; 2005.
20. MGI Pharma Inc. Hexalen (altretamine) oral capsules product information. Bloomington, MN; 2001.
21. Novartis Pharmaceuticals Corporation. Cytadren (aminoglutethimide) oral tablets product information. East Hanover, NJ; 2002.
22. Thompson TA, Vermeulen JD, Wagner WE Jr, Le Sher AR. Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents. J Pharm Sci 1981;70:1040-3.
23. AstraZeneca Pharmaceuticals LP. Arimidex (anastrozole) oral tablet product information. Wilmington, DE; 2009.
24. Prometheus Laboratories, Inc. Imuran (azathioprine) scored oral tablet, IV injection product information. San Diego, CA; 2008.
25. Dressman JB, Poust RI. Stability of allopurinol and of five antineoplastics in suspension. Am J Hosp Pharm 1983;40:616-18.
26. Allen LV Jr, Erickson MA III. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996;53:1944-9.
27. Eisai Inc. Targretin (bexarotene) oral capsule product information. Woodcliff Lake, NJ; 2007.
28. Eisai Inc. Data on file, Targretin (bexarotene). Woodcliff Lake, NJ; 2008.
29. AstraZeneca Pharmaceuticals LP. Casodex (bicalutamide) oral tablet product information. Wilmington, DE; 2009.
30. GlaxoSmithKline. Myleran (busulfan) oral tablet product information. Research Triangle Park, NC; 2005.
31. PDL BioPharma, Inc. Busulfex (busulfan) IV injection product information. Redwood City, CA; 2007.
32. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003;52:209-16.
33. Allen LV. Busulfan oral suspension. US Pharm 1990;15:94-5.
34. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001;28:1013-18.
35. Roche Laboratories Inc. Xeloda (capecitabine) oral tablet product information. Nutley, NJ; 2006.
36. Hoffman-La Roche Inc. Xeloda (capecitabine) data on file. Nutley, NJ; 2004.
37. GlaxoSmithKline. Leukeran (chlorambucil) oral tablet product information. Research Triangle Park, NC; 2006.
38. Bristol-Myers Squibb. Cytoxan (cyclophosphamide) injection, oral tablet product information. Princeton, NJ; 2005.
39. Brook D, Davis RE, Bequette RJ. Chemical stability of cyclophosphamide in aromatic elixir U.S.P. Am J Health Syst Pharm 1973,30:618-20.
40. Kennedy R, Groepper D, Tagen M, et al. Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother 2010;44:295-301.
41. Allen LV Jr. Cyclophosphamide 10-mg/ml oral liquid. US Pharm 2010;35:42-3.
42. Bristol-Myers Squibb. Sprycel (dasatinib) oral tablet product information. Princeton, NJ; 2009.
43. Bristol-Myers Squibb. Sprycel (dasatinib) data on file. Princeton, NJ; 2010.
44. OSI Pharmaceuticals Inc. Tarceva (erlotinib) oral tablet product information. Melville, NY; 2009.
45. Genetech (OSI) Oncology, Inc. Tarceva (erlotinib) data on file. South San Francisco, CA; 2008.
46. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada clinical trials group study. J Clin Oncol 2007;25:2178-83.
47. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85. (Pubitemid 41095117)
48. Pharmacia and Upjohn Company. Emcyt (estramustine phosphate sodium) oral capsule product information. New York, NY; 2008.
49. Bristol-Myers Squibb. Vepesid (etoposide) injection, oral capsule product information. Princeton, NJ; 2004.
50. McLeod HL, Relling MV. Stability of etoposide solution for oral use. Am J Hosp Pharm 1992;49:2784-5.
51. Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin Pharmacol Ther 1995;58:99-107.
52. Aguilar Ponce JL, Flores-Picazo Y, Pérez - Urizar J, et al. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. Arch Med Res 1999;30:212-15.
53. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.
54. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002;58:491-4. (Pubitemid 35244924)
55. Pharmacia and Upjohn Company. Aromasin (exemestane) oral tablets product information. New York, NY; 2007.
56. Novartis Pharmaceuticals Corporation. Afinitor (everolimus) oral tablets product information. East Hanover, NJ; 2009.
57. Merck & Co., Inc. Proscar (finasteride) oral tablet product information. Whitehouse Station, NJ; 2004.
58. Merck & Co., Inc. Propecia (finasteride) oral tablet product information. Whitehouse Station, NJ; 2007.
59. Bayer HealthCare Pharmaceuticals Inc. Fludara (fludarabine phosphate) IV injection product information. Wayne, NJ; 2009.
60. Antisoma Research Limited. Fludarabine phosphate film-coated oral tablet product information. Cambridge, MA; 2008.
61. Schering Corporation. Eulexin (flutamide) oral capsule product information. Kenilworth, NJ; 2001.
62. AstraZeneca Pharmaceuticals. Iressa (gefitinib) oral tablet product information. Wilmington, DE; 2005.
63. Bristol-Myers Squibb. Hydrea (hydroxyurea) oral capsule product information. Princeton, NJ; 2005.
64. Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004;26:179-84.
65. Novartis Pharmaceuticals Corporation. Gleevec (imatinib mesylate) oral tablet product information. East Hanover, NJ; 2009.
66. Roche Laboratories Inc. Accutane (isotretinoin) oral capsule product information. Nutley, NJ; 2007.
67. St. Jude Children's Research Hospital. Patient medication. Isotretinoin. Available from www.stjude.org/SJFile/isotretinoin.pdf. Accessed February 24, 2010.
68. GlaxoSmithKline. Tykerb (lapatinib) oral tablet product information. Research Triangle Park, NC; 2008.
69. Celgene Corporation. Revlimid (lenalidomide) oral capsule product information. Summit, NJ; 2009.
70. Novartis Pharmaceuticals Corporation. Femara (letrozole) oral tablet product information. East Hanover, NJ; 2008.
71. Bristol-Myers Squibb. Ceenu (lomustine) oral capsule product information. Princeton, NJ; 2004.
72. PAR Pharmaceutical Inc. Megace (megestrol acetate) tablet product information. Spring Valley, NY; 2004.
73. Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine 2009;4:185-92.
74. Martin TP, Hayes P, Collins DM. Tablet dispersion as an alternative to formulation of oral liquid dosage forms. Aust J Hosp Pharm 1993;23:378-86. (Pubitemid 24028275)
75. GlaxoSmithKline. Alkeran (melphalan) oral tablet, (melphalan hydrochloride) IV injection product information. Research Triangle Park, NC; 2008.
76. Bristol-Myers Squibb. Lysodren (mitotane) oral tablet product information. Princeton, NJ; 2009.
77. Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D. Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 1981;7:51-4. (Pubitemid 12253946)
78. GlaxoSmithKline. Purinethol (mercaptopurine) oral tablet product information. Research Triangle Park, NC; 2002.
79. Aliabadi HM, Romanick M, Desai S, Lavasanifar A. Effect of buffer and antioxidant on stability of a mercaptopurine suspension. Am J Health Syst Pharm 2008;65:441-7. (Pubitemid 351358346)
80. Stada Pharmaceuticals Inc. Rheumatrex (methotrexate sodium) oral tablet product information. Cranbury, NJ; 2003.
81. Mayne Pharma. Methotrexate sodium injection, USP product information. Paramus, NJ; 2005.
82. Harvey VJ, Slevin ML, Woollard RC, et al. The bioavailability of oral intermediate-dose methotrexate: effect of dose subdivision, formulation, and timing in the chemotherapy cycle. Cancer Chemother Pharmacol 1984;13:91-4.
83. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low-dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9. (Pubitemid 24031585)
84. Stuart JFB, Calman KC, Paxton J, et al. Bioavailability of methotrexate: implications for clinical use. Cancer Chemother Pharmacol 1979;3:239-41.
85. Marshall PS, Gertner E. Oral administration of an easily prepared solution of injectable methotrexate diluted in water: a comparison of serum concentrations vs methotrexate tablets and clinical utility. J Rheumatol 1996;23:455-8. (Pubitemid 26101585)
86. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) oral capsule product information. East Hanover, NJ; 2009.
87. Yin OQ, Gallagher N, Li A, Zhou W, Harrell R, Schran H. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2010;50:188-94.
88. GlaxoSmithKline. Votrient (pazopanib) oral tablet product information. Research Triangle Park, NC; 2009.
89. Sigma-Tau Pharmaceuticals, Inc. Matulane (procarbazine hydrochloride) oral capsule product information. Gaithersburg, MD; 2002.
90. Sigma-Tau Pharmaceuticals, Inc. Matulane (procarbazine hydrochloride) data on file. Gaithersburg, MD; 2010.
91. Eli Lilly and Company. Evista (raloxifene hydrochloride) oral tablet product information. Indianapolis, IN; 2007.
92. Bayer HealthCare Pharmaceuticals Inc. Nexavar (sorafenib) oral tablet product information. Wayne, NJ; 2009.
93. Bayer HealthCare Pharmaceuticals Inc. Nexavar (Sorafenib) data on file. Wayne, NJ; 2010.
94. Pfizer Labs. Sutent (sunitinib maleate) oral capsule product information. New York, NY; 2008.
95. Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Stability of sunitinib in oral suspension. Ann Pharmacother 2008;42:962-6.
96. Sistla A, Sunga A, Phung K, Koparkar A, Shenoy N. Powderin-bottle formulation of SU011248: enabling rapid progression into human clinical trials. Drug Dev Ind Pharm 2004;30:19-25. (Pubitemid 38240472)
97. van Erp NP, Baker SD, Zandvliet AS, et al. Marginal increase of sunitinib exposure by grapefruit juice [published online ahead of print May 29, 2010]. Cancer Chemother Pharmacol. Available from http://www.springerlink.com/content/ p8087 0j34 3431/.
98. AstraZeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) oral tablet product information. Wilmington, DE; 2006.
99. Schering Corporation. Temodar (temozolomide) IV injection, oral capsule product information. Kenilworth, NJ; 2009.
100. Trissel LA, Yanping Z, Koontz SE. Temozolomide stability in extemporaneously compounded oral suspension. Int J Pharm Compounding 2006;10:396-9.
101. Celgene Corporation. Thaliomid (thalidomide) oral capsule product information. Summit, NJ; 2007.
102. GlaxoSmithKline. Tabloid (thioguanine) oral tablet product information. Research Triangle Park, NC; 2004.
103. GlaxoSmithKline. Hycamtin (topotecan hydrochloride) IV injection, oral capsule product information. Research Triangle Park, NC; 2007.
104. GTx Inc. Fareston (toremifene citrate) oral tablet product information. Memphis, TN; 2004.
105. Roche Pharmaceuticals. Vesanoid (tretinoin) oral capsule product information. Nutley, NJ; 2008.
106. Bargetzi MJ, Tichelli A, Gratwohl A, Speck B. Oral all-transretinoic acid administration in intubated patients with acute promyelocytic leukemia [in German]. Schweiz Med Wochenschr 1996;126:1944-5. (Pubitemid 26376936)
107. Shaw PJ, Atkins MC, Nath CE, Earl JW. ATRA administration in the critically ill patient [letter]. Leukemia 1995;9:1288.
108. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG. Variability in the oral bioavailability of all-transretinoic acid. J Natl Cancer Inst 1993;85:993-6. (Pubitemid 23177586)
109. Children's Hospitals and Clinics of Minnesota. Patient/family education. Retinoic acid (for cancer therapy): tretinoin and isotretinoin. Available from www.childrensmn.org/Manuals/PFS/Med/018907.pdf. Accessed February 19, 2010.
110. Merck and Co., Inc. Zolinza (vorinostat) oral capsule product information. Whitehouse Station, NJ; 2006.
111. Merck and Co., Inc. Zolinza (vorinostat) data on file. North Wales, PA; 2010.
112. Apotex Inc. Allopurinol oral tablet product information. Toronto, ON; 2005.
113. Bedford Laboratories. Allopurinol sodium IV injection product information. Bedford, OH; 2004.
114. Alexander KS, Dawar N, Parker GA. Stability of allopurinol suspension compounded from tablets. Int J Pharm Comp 1997;1:128-31.
115. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992;93:299-302.
116. Merck and Co., Inc. Emend (aprepitant) oral capsule, (fosaprepitant dimeglumine) intravenous injection product information. Whitehouse Station, NJ; 2009.
117. Merck and Co., Inc. Emend (aprepitant) data on file. North Wales, PA; 2008.
118. Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer 2009;17:701-6.
119. Aventis Pharmaceuticals Inc. Anzemet (dolasetron mesylate) intravenous solution, oral tablet product information. Kansas City, MO; 2003.
120. Johnson CE, Wagner DS, Bussard WE. Stability of dolasetron in two oral liquid vehicles. Am J Health Syst Pharm 2003;60:2242-4.
121. GlaxoSmithKline. Promacta (eltrombopag) oral tablets product information. Research Triangle Park, NC; 2008.
122. Roche Laboratories Inc. Kytril (granisetron hydrochloride) IV injection, oral solution, oral tablet product information. Nutley, NJ; 2009.
123. ProStrakan Inc. Sancuso (granisetron) transdermal system product information. Bedminster, NJ; 2008.
124. Quercia RA, Zhang J, Fan C, et al. Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid. Am J Health Syst Pharm 1997;54:1404-6. (Pubitemid 27260178)
125. Nahata MC, Morosco RS, Hipple TF. Stability of granisetron hydrochloride in two oral suspensions. Am J Health Syst Pharm 1998;55:2511-13.
126. Bedford Laboratories. Leucovorin calcium IV injection product information. Bedford, OH; 2000.
127. Roxane Laboratories Inc. Leucovorin calcium oral tablet product information. Columbus, OH; 2007.
128. Bristol-Myers Squibb Oncology. Mesnex (mesna) IV injection, oral tablet product information. Princeton, NJ; 2002.
129. Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998;6:144-54.
130. Goren MP, Lyman BA, Li JT. The stability of mesna in beverages and syrup for oral administration. Cancer Chemother Pharmacol 1991;28:298-301.
131. GlaxoSmithKline. Zofran (ondansetron hydrochloride) oral tablets, oral solution, orally disintegrating tablets product information. Research Triangle Park, NC; 2006.
132. Sandoz Inc. Ondansetron oral tablet, orally-disintegrating tablet product information. Broomfield, CO; 2006.
133. Graham CL, Dukes GE, Fox JL, Kao CF, Hak LJ. Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions. Am J Hosp Pharm 1993;50:106-8.
134. Allen LV Jr. Ondansetron hydrochloride 0.8 mg/ml oral liquid. US Pharm 2009;34:38-9.
135. Pfizer & Upjohn Company. Cyklokapron (tranexamic acid) IV injection product information. New York, NY; 2008.
136. Xanodyne Pharmaceuticals Inc. Lysterda (tranexamic acid) oral tablet product information. Newport, KY; 2009.
137. Sindet-Pedersen S, Ingerslev J, Ramström G, Blombäck M. Management of oral bleeding in haemophilic patients [letter]. Lancet 1988;2:566.
138. PharmInfoTech. Formulation in pharmacy practice, 2nd ed. Extemporaneous oral liquid preparation of tranexamic acid mouthwash. Available from http://www.pharminfotech.co.nz/manual/Formulation/mixtures/tranexamic-acid.html. Accessed January 12, 2010.
139. Sindet-Pedersen S. Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol 1987;27:1005-8.
140. Allen LV. The art and science of pharmaceutical compounding, 2nd ed. Washington, DC: APhA Publications, 2005:493.
141. Allen LV. Compounding, stability and beyond-use dates. Secundum Artem, vol 7, no. 3. Minneapolis, MN: Paddock Laboratories. Available from www.paddocklabs.com. Accessed February 24, 2010.
142. Nahata MC, Allen LV Jr. Extemporaneous drug formulations. Clin Ther 2008;30:2112-19.
143. Woods DJ. Extemporaneous formulations: problems and solutions. Paediatr Perinatal Drug Ther 1997;1:25-9.
144. Allen LV Jr, Erickson MA III. Stability of extemporaneously prepared pediatric formulations using Ora-Plus with Ora-Sweet and Ora-Sweet SF - part I. Secundum Artem, vol 5, no. 4. Minneapolis, MN: Paddock Laboratories. Available from http://www.paddock labs.com/secundum-artem.html. Accessed February 10, 2010.
145. Nahata MC. Safety of "inert" additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonatal Ed 2009;94:F392-3.
146. United States Pharmacopeial Convention. The United States Pharmacopeia, 29th rev, and the National Formulary, 24th ed. Rockville, MD: United States Pharmacopeial Convention, 2006:1348.
147. Elion GB, Callahan S, Bieber S, et al. A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl)thio] purine (BM 57-322). Cancer Chemother Rep 1961;14:93-8.
148. Chang SY, Alberts DS, Farquhar D, Melnick LR, Walson PD, Salmon SE. Hydrolysis and protein binding of melphalan. J Pharm Sci 1978;67:682-4.
149. Flora KP, Smith SL, Cradock JC. Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. J Chromatogr 1979;177:91-7.
150. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67.
151. Centers for Disease Control and Prevention, Department of Health and Human Services. National Institute for Occupational Safety and Health (NIOSH) alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. NIOSH publication no. 2004-1 5, September 2004. Available from www.cdc.gov/niosh/docs/2004-165. Accessed March 29, 2010.
152. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice - drug interactions. Br J Clin Pharmacol 1998;46:101-10.
153. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-72. (Pubitemid 28177290)
154. Greenblatt DJ. Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides. J Clin Pharmacol 2009;49:1403-7.
155. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005;28:677-94. (Pubitemid 41132455)
156. Farkas D, Greenblatt DJ. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008;4:381-93. (Pubitemid 351728513)
157. National Patient Safety Agency. National reporting and learning service. Patient safety alert: promoting safer measurement and administration of liquid medicines via oral and other enteral routes. March 28, 2007;19:1-12. Available from www.nrls.npsa.nhs.uk/resources/?entryid45=59808&p=5. Accessed February 24, 2010.
158. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm 2008;65:2347-57.
159. Magnuson BL, Clifford TM, Hoskins LA, Bernard AC. Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract 2005;20:618-24.
160. American Society of Health-System Pharmacists Council on Pofessional Affairs. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm 2006;63:1172-91.
161. United States Pharmacopeia. Commentary to revision bulletin for general chapter pharmaceutical compounding - sterile preparations. Chapter 797. Available from http://www.usp.org/pdf/EN/USPNF/general-Chapter797Commentary.pdf. Accessed July 21, 2010.
162. Giacoia GP, Taylor-Zapata P, Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation initiative: selected reports from working groups. Clin Ther 2008;30:2097-101.
163. Treadway AK, Craddock D, Leff R. Practices of pharmacies that compound extemporaneous formulations. Am J Health Syst Pharm 2007;64:1403-9. (Pubitemid 47025540)
164. Siracuse MV, Schondelmeyer SW, Hadsall RS, Schommer JC. Third-year pharmacy students' work experience and attitudes and perceptions of the pharmacy profession. Am J Pharm Educ 2008;72:1-9 (article 50).
165. U.S. Food and Drug Administration. Pharmacy compounding: 200 limited FDA survey of compounded drug products. Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm. Accessed July 13, 2010.
166. O'Bryant CL, Crandell BC. Community pharmacists' knowledge of and attitudes toward oral chemotherapy. J Am Pharmacists Assoc 2008;48:632-9.
167. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61. (Pubitemid 34552485)
168. Taylor JA, Winter L, Geyer LJ, Hawkins DS. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 2006;107:1400-6.
169. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76.
170. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990;8:356-64.
171. Fransman W, Roeleveld N, Peelen S, de Kort W, Kromhout H, Heederik D. Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes. Epidemiology 2007;18:112-19.
172. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985;313:1173-8.
173. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999;41:632-8.
174. Valanis B, Vollmer W, Labuhn K, Glass A. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med 1997;39:574-80.
175. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993;50:455-62.
176. Dranitsaris G, Johnston M, Poirier S, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Practice 2005;11:69-78.
177. Martin S. The adverse health effects of occupational exposure to hazardous drugs. Community Oncol 2005;2:397-400.
178. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs 2007;30:112-22.
179. Malbasa T, Kodish E, Santacroce SJ. Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 2007;24:139-51.
180. Macintosh PW, Pond GR, Pond BJ, Leung V, Siu LL. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care 2007;16:380-6.
181. McPherson CJ, Higginson IJ, Hearn J. Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 2001;23:227-34.
182. Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C. Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 2010;18:583-90.